B7-33 is a peptide analog containing aliphatic, aromatic, and charged residues that influence backbone flexibility and structural dynamics. Researchers use it to study ligand-protein recognition, folding transitions, and intermolecular interactions. Its sequence promotes helix formation under selective environments. The motif supports advanced mechanistic exploration.
B7-33 is a synthetic peptide derivative designed as an analog of the human relaxin-2 hormone, specifically corresponding to the B-chain segment. As a bioactive peptide, it has garnered significant attention within molecular pharmacology and peptide research due to its ability to selectively activate the relaxin family peptide receptor 1 (RXFP1) while exhibiting reduced affinity for other relaxin receptors. The unique structural modifications of B7-33 confer distinct signaling properties, making it a valuable tool for dissecting relaxin-mediated pathways without eliciting the full spectrum of native hormone effects. Its application in experimental systems has enabled researchers to probe the nuanced roles of relaxin signaling in diverse physiological and cellular contexts, offering new perspectives on peptide-receptor interactions and downstream biochemical events.
Receptor signaling studies: B7-33 serves as an important molecular probe for investigating the RXFP1 receptor and its associated signaling cascades. By acting as a selective agonist, it allows scientists to isolate and characterize the effects of RXFP1 activation independently from other relaxin family receptors. This selectivity is particularly advantageous for elucidating the receptor's role in cAMP production, ERK1/2 phosphorylation, and other intracellular responses. The use of B7-33 in receptor signaling assays enables a more precise understanding of relaxin-driven pathways, supporting both basic research and the development of receptor-specific modulators.
Peptide structure-activity relationship (SAR) analysis: The design and functional characterization of B7-33 provide valuable insights for SAR studies within the relaxin peptide family. Its engineered sequence facilitates the mapping of key amino acid residues responsible for receptor binding affinity, specificity, and downstream signaling bias. Researchers employ B7-33 to systematically compare its activity profile against native relaxin peptides and other analogs, advancing the rational design of next-generation peptide ligands with tailored pharmacological properties.
Cell-based functional assays: In vitro studies utilizing B7-33 have become instrumental in assessing cellular responses to RXFP1 activation. By applying this peptide to cultured cell systems expressing the target receptor, investigators can monitor changes in gene expression, second messenger levels, and other functional endpoints. Such assays are critical for delineating the cellular mechanisms modulated by RXFP1 and for screening the efficacy of novel compounds intended to modulate this pathway.
Biochemical mechanism elucidation: The selective action of B7-33 enables detailed mechanistic studies focused on the downstream events following RXFP1 engagement. Researchers leverage the peptide to dissect the molecular interplay between receptor activation and intracellular signaling networks, including the modulation of G protein-coupled pathways and cross-talk with other cellular effectors. These mechanistic insights help clarify the broader physiological significance of relaxin signaling and inform the design of targeted interventions in research settings.
Peptide-based drug discovery platforms: B7-33 is frequently employed as a reference ligand or lead compound in preclinical drug discovery efforts centered on peptide therapeutics targeting RXFP1. Its well-characterized pharmacological profile and receptor selectivity make it an ideal benchmark for evaluating the binding and functional properties of novel peptide analogs. By incorporating B7-33 into screening platforms, researchers can efficiently identify candidates with optimized activity, improved stability, or unique signaling attributes, thereby accelerating the development of innovative peptide-based research tools and molecular probes.
1. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
2. Emu oil in combination with other active ingredients for treating skin imperfections
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More